Literature DB >> 23560282

Definitive surgical treatment of enterocutaneous fistula: outcomes of a 23-year experience.

Rachel M Owen1, Timothy P Love, Sebastian D Perez, Jahnavi K Srinivasan, Jyotirmay Sharma, Jonathan D Pollock, Carla I Haack, John F Sweeney, John R Galloway.   

Abstract

OBJECTIVE: To analyze postoperative outcomes, morbidity, and mortality following enterocutaneous fistula (ECF) takedown. DESIGN, SETTING, AND PATIENTS: Retrospective review of the complete medical records of patients who presented to a single tertiary care referral center from December 24, 1987, to June 18, 2010, and subsequently underwent definitive surgical treatment for ECF originating from the stomach, small bowel, colon, or rectum. MAIN OUTCOME MEASURES: Postoperative fistula recurrence and mortality.
RESULTS: A total of 153 patients received operative intervention for ECF. Most ECFs were referred to us from outside institutions (75.2%), high output (52.3%), originating from the small bowel (88.2%), and iatrogenic in cause (66.7%). Successful ECF closure was ultimately achieved in 128 patients (83.7%). Six patients (3.9%) died within 30 days of surgery, and overall 1-year mortality was 15.0%. Postoperative complications occurred in 134 patients, for an overall morbidity rate of 87.6%. Significant risk factors for fistula recurrence were numerous, but postoperative ventilation for longer than 48 hours, organ space surgical site infection, and blood transfusion within 72 hours of surgery carried the most considerable impact (relative risks, 4.87, 4.07, and 3.91, respectively; P < .05). Risk of 1-year mortality was also associated with multiple risk factors, the most substantial of which were postoperative pulmonary and infectious complications. Closure of abdominal fascia was protective against both recurrent ECF and mortality (relative risks, 0.47 and 0.38, respectively; P < .05).
CONCLUSIONS: Understanding risk factors both associated with and protective against ECF recurrence and postoperative morbidity and mortality is imperative for appropriate ECF management. Closure of abdominal fascia is of utmost importance, and preventing postoperative complications must be prioritized to optimize patient outcomes.

Entities:  

Mesh:

Year:  2013        PMID: 23560282     DOI: 10.1001/2013.jamasurg.153

Source DB:  PubMed          Journal:  JAMA Surg        ISSN: 2168-6254            Impact factor:   14.766


  20 in total

Review 1.  Practical Approaches to Definitive Reconstruction of Complex Abdominal Wall Defects.

Authors:  Rifat Latifi
Journal:  World J Surg       Date:  2016-04       Impact factor: 3.352

2.  Effect of Preoperative Administration of Oral Arginine and Glutamine in Patients with Enterocutaneous Fistula Submitted to Definitive Surgery: a Prospective Randomized Trial.

Authors:  Jose L Martinez; Ilka Bosco-Garate; Luis Manuel Souza-Gallardo; José D Méndez; Marco A Juárez-Oropeza; Ruben Román-Ramos; Eduardo Ferat-Osorio
Journal:  J Gastrointest Surg       Date:  2019-02-01       Impact factor: 3.452

3.  Letter to the Editor: Management of Enterocutaneous Fistula: Outcomes in 276 Patients.

Authors:  Stephanie Pham; Todd W Canada
Journal:  World J Surg       Date:  2018-12       Impact factor: 3.352

4.  Surgery for post-operative entero-cutaneous fistulas: is bowel resection plus primary anastomosis without stoma a safe option to avoid early recurrence? Report on 20 cases by a single center and systematic review of the literature.

Authors:  A Lauro; R Cirocchi; N Cautero; A Dazzi; D Pironi; F M Di Matteo; A Santoro; S Faenza; L Pironi; A D Pinna
Journal:  G Chir       Date:  2017 Jul-Aug

5.  Effect of Oral ω3-Polyunsaturated Fatty Acids as a Complement Management to Control Fistula Output and Inflammation in Patients With Digestive Fistula.

Authors:  José Luis Martínez-Ordaz; Ilka Boscó-Gárate; Arturo Cérbulo-Vázquez; Lourdes Arriaga-Pizano; Isabel Wong-Baeza; Patricio Sánchez-Fernandez; Constantino López-Macías; Armando Isibasi; Eduardo Ferat-Osorio
Journal:  J Gastrointest Surg       Date:  2016-12-01       Impact factor: 3.452

Review 6.  Treatment of enterocutaneous fistula: a systematic review and meta-analysis.

Authors:  R Gefen; Z Garoufalia; P Zhou; K Watson; S H Emile; S D Wexner
Journal:  Tech Coloproctol       Date:  2022-08-01       Impact factor: 3.699

7.  Management of Enterocutaneous Fistula: Outcomes in 276 Patients.

Authors:  Martha Quinn; Stuart Falconer; Ruth F McKee
Journal:  World J Surg       Date:  2017-10       Impact factor: 3.352

8.  Bridging-to-Surgery in Patients with Type 2 Intestinal Failure.

Authors:  Fleur E E de Vries; Jeroen J M Claessen; Elina M S van Hasselt-Gooijer; Oddeke van Ruler; Cora Jonkers; Wanda Kuin; Irene van Arum; G Miriam van der Werf; Mireille J Serlie; Marja A Boermeester
Journal:  J Gastrointest Surg       Date:  2020-07-22       Impact factor: 3.452

9.  Enterocutaneous fistula after emergency general surgery: Mortality, readmission, and financial burden.

Authors:  Justin S Hatchimonji; Jesse Passman; Elinore J Kaufman; Catherine E Sharoky; Lucy W Ma; Dane Scantling; Ruiying Xiong; Daniel N Holena
Journal:  J Trauma Acute Care Surg       Date:  2020-07       Impact factor: 3.697

10.  Reducing pre-operative length of stay for enterocutaneous fistula repair with a multi-disciplinary approach.

Authors:  Mark Chamberlain; Rebecca Dwyer
Journal:  BMJ Qual Improv Rep       Date:  2015-01-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.